A Systematic Review and Meta-Analysis: Safety and Efficacy of Cediranib in the Treatment of Cancer Patients

Table 3

Adverse and safety profile.

	Studies	Cediranib- containing therapy	Control	RR (95% CI)	value	I^2 (%)
Fatigue	13	1213 of 2255	821 of 1781	1.14 (1.03–1.25)	0.008	58.1	Random
Diarrhea	13	1547 of 2259	747 of 1814	1.96 (1.65–2.33)	<0.001	77.2	Random
Hypertension	12	981 of 2197	337 of 1752	2.73 (2.00–2.71)	<0.001	79.8	Random
Nausea	11	1146 of 2010	850 of 1627	1.05 (0.99–1.12)	0.084	0.0	Fixed
Neutropenia	10	920 of 2049	550 of 1613	1.30 (1.20–1.41)	<0.001	30.1	Fixed
Thrombocytopenia	10	715 of 2049	346 of 1613	1.53 (1.37–1.70)	<0.001	49.0	Fixed
Anorexia	8	637 of 1665	450 of 1524	1.27 (1.16–1.40)	<0.001	39.1	Fixed
Stomatitis	8	513 of 1656	307 of 1480	1.54 (1.36–1.74)	<0.001	10.9	Fixed
Vomiting	8	588 of 1584	448 of 1448	1.17 (1.06–1.30)	0.002	27.8	Fixed
Sensory neuropathy	7	701 of 1617	643 of 1478	1.03 (0.95–1.2)	0.442	0.0	Fixed
Constipation	7	343 of 1441	357 of 1226	0.87 (0.76–0.98)	0.023	46.9	Fixed
Anemia	7	202 of 515	207 of 436	0.96 (0.85–1.07)	0.447	38.1	Fixed
Leukopenia	5	117 of 319	86 of 236	1.17 (0.97–1.40)	0.095	0.0	Fixed
Hand-foot syndrome	4	176 of 835	75 of 692	2.17 (1.31–3.58)	0.002	52.8	Random
Headache	4	59 of 160	15 of 130	2.78 (1.69–4.58)	<0.001	35.9	Fixed
Abdominal pain	4	343 of 1299	245 of 1159	1.24 (1.08–1.43)	0.003	0.0	Fixed
Dyspnea	3	148 of 309	126 of 311	1.17 (0.99–1.38)	0.072	10.0	Fixed
Venous thromboembolism	3	25 of 500	10 of 285	1.66 (0.75–3.68)	0.207	23.0	Fixed
Dysphonia	3	74 of 262	13 of 229	5.43 (1.25–23.61)	0.024	73.9	Random
Epistaxis	3	191 of 808	181 of 809	1.38 (0.68–2.81)	0.369	60.4	Random